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 Alzheimer’s disease (AD) is the most common type of de-
mentia. Recent studies have assessed the possibility of using 
statins as treatment for AD. However, their effi cacy is not 
clear. In this study, we collected the most relevant informa-
tion about the effi cacy of statins for the treatment of AD. 
We conducted a systematic literature search using MEDLINE, 
EMBASE and The Cochrane Library. We included clinical tri-
als, meta-analyses and systematic reviews that analysed the 
effi cacy of statins in AD. We also extracted the characteris-
tics and effi cacy results of the studies selected. Of the 304 
articles identifi ed, 13 complied with the inclusion criteria. The 
scientifi c quality of studies was high and their results indi-
cated that there were no signifi cant differences in the main 
effi cacy variables between statins and placebo treatment for 
AD. Therefore, according to the available scientifi c evidence, 
statins have not shown an improvement in cognition and do 
not appear to offer signifi cant benefi ts to patients with AD. 
 KEYWORDS :  Alzheimer’s disease ,  statins ,  effi cacy ,  systematic 
review 
 Introduction 
 Alzheimer’s disease (AD) is the most common type of dementia. It 
is a neurodegenerative pathology, whose incidence has increased 
in the past few years. With an estimated prevalence of 46.8 
million cases worldwide in 2015, the number of patients with AD is 
expected to continue to increase in the coming years. 1 
 There are two main manifestations of AD: early-onset AD, which 
especially affects young people, and late-onset AD, which is more 
common and occurs mainly in older people, usually patients over 
65 years old; therefore, ageing is considered to be the main risk 
factor for the disease. 2 
 Pathologically, AD is associated with pronounced brain atrophy 
and an excessive amount of neuritic plaques, which contain 
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protein and extracellular deposits of β-amyloid (Aβ). 3 When these 
deposits accumulate in the cerebral cortex, they cause neurotoxic 
effects. 
 Aβ peptides derive from the amyloid precursor protein (APP) in 
response to the activity of secretases (α-SAPP, β-SAPP and γ-SAPP), 
which cleave the APP into different fragments. 4 These secretases 
have been the subject of scientific research because of their role in 
the regulation of Aβ. 5 
 Aβ deposits contain apolipoprotein E (apoE), a peptide found 
in the chylomicron, and very low-density lipoprotein (VLDL), 
which travels through the plasma transporting cholesterol to its 
receptors. In addition, apoE promotes the conversion of Aβ into 
its insoluble form, generating neuritic plaques in patients with AD. 
Hence, the appearance of plaques should be directly proportional 
to the levels of apoE in the central nervous system. 6 Therefore, 
polymorphism of the gene encoding apoE could indicate a risk 
of developing late-onset AD, given that apoE4 is associated 
with higher LDL cholesterol levels, which are involved in the 
accumulation of Aβ. 7 
 Currently, there is no effective curative treatment for AD 
and the management of the disease is aimed at improving its 
symptoms. Drugs such as cholinesterase inhibitors (galantamine or 
rivastigmine) manage to slow the progression of the disease, but 
are only useful during the early stages of the disease. Memantine, 
a  N -methyl-D-aspartic (NMDA) receptor antagonist, is effective 
during the advanced stages of the disease, protecting nerve cells 
in the brain from glutamate, a neurotransmitter that is released in 
excessive amounts in AD. 8 
 Statins are hydroxymethylglutaryl coenzyme A reductase 
inhibitors that reduce cholesterol synthesis and increase the 
number of LDL receptors in hepatocyte membranes, enabling 
greater clearance of LDL from the bloodstream and lowering 
the level of lipoproteins. 9 These are the drugs of choice for the 
treatment of hypercholesterolemia. 
 According to previous studies, patients treated with statins have 
a lower risk of developing AD. 10,11 In addition, some experimental 
studies have shown that statins treatment delays the progression 
of AD because they reduce the production of Aβ and, therefore, 
the decrease in cholesterol levels appears to inhibit the formation 
of the same. 6,12 
 However, the efficacy of such drugs is not clear, given that the 
results of the latest clinical trials did not reflect an improvement 
on the parameters that are used to measure the cognitive 
impairment of patients. Nevertheless, some clinical guidelines 
for the treatment of AD consider the use of statins as a possible 
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treatment option for this pathology and some studies suggest its 
efficacy as treatment for certain subpopulations with AD. 13,14 
 Given the above, and because of the high prevalence of AD and 
high frequency of publications respect to the use of statins in 
patients with AD, it would be necessary to perform a systematic 
assessment of its efficacy to identify possible subpopulations of 
patients who could benefit most from statin therapy. 
 For the above-mentioned reasons, the main objective of this 
review was to compile the most relevant information about 
the efficacy of the use of statins for the treatment of patients 
with AD. 
 Methods 
 Selection criteria 
 In concordance with the Preferred Reporting Items for Systematic 
Reviews and Meta-Analysis (PRISMA) guidelines, 15 we conducted 
a systematic search of the literature published between January 
2010 and April 2016 in the main biomedical databases MEDLINE 
(PubMed), EMBASE and The Cochrane Library. The search strategy 
is detailed as supplementary material. 
 We complemented our literature search by consulting different 
websites of drug regulatory agencies and scientific societies, and 
looking for new references within the documents found. 
 We included clinical trials, meta-analyses and systematic reviews 
that determined the efficacy of statins in AD, using parameters 
associated with the cause or the evaluation of the pathology, in 
patients diagnosed with AD and aged 18 or older. 
 Articles based on a different study design, those that evaluated 
the efficacy of the use of statins for the prevention of AD, and 
those written in languages other than English or Spanish were 
excluded. 
 Study selection and quality assessment 
 In a first phase, duplicates were eliminated. Then, eligible articles 
were selected based on information obtained from the title, 
abstract or full text, if necessary. 
 To ensure reproducibility and minimise bias, discrepancies were 
resolved by a second researcher. Subsequently, a critical reading of 
the selected articles was performed. 
 To assess the quality and validity of the clinical trials, we used 
the Spanish version of the Critical Appraisal Skills Programme 
(CASP) scale: the CASPe scale. 16 The quality of the studies was 
scored on a 0–6 scale, where 0 = negative or doubtful (no explicit 
information) and >1 = positive response; more specifically: <3 
= low quality, 3 = medium–low quality, 4 = medium quality, 5 = 
medium–high quality, 6 = high quality. We used the AMSTAR tool 
to assess the quality of systematic reviews and meta-analyses. 17 
The score percentage was divided by 10 instead of 11 if the 
systematic review was rated as ‘not applicable’ on item 10, related 
to publication bias. The AMSTAR score percentage was used to 
classify the methodological quality of the study. A percentage of 
0–33% was classified as low quality; 34–66%, as medium quality; 
and 67–100%, as high quality. 
 Data extraction and outcomes 
 A descriptive analysis of the main characteristics of the studies 
selected was captured in an ad hoc table, considering the 
following variables: study design, number of patients included, 
selection criteria, characteristics of pathology and treatment 
regimens evaluated. 
 The following efficacy variables were considered: 
 > Mini-Mental State Examination (MMSE) score 
 > AD Assessment Scale - Cognitive Portion (ADAS-Cog) score 
 > Change in Neuropsychiatric Inventory (NPI) total score 
 > AD Cooperative Study - Clinical Global Impression of Change 
(ADCS-CGIC) score 
 > Analytical variables indicating AD: levels of Aβ40 and Aβ42 in 
plasma and in cerebrospinal fl uid (CSF), total tau protein and 
phosphorylated tau protein levels, soluble amyloid precursor 
protein-beta (sAPP-b), soluble amyloid precursor protein-alpha 
(sAPP-a) and plasma levels of 24S-hydroxycholesterol. 
 Statistical analysis 
 The statistical analysis was carried out using Microsoft Excel 
2007® and IBM SPSS Statistics 21®. Qualitative variables 
were represented as percentages and quantitative variables 
were represented by measures of central tendency (mean) and 
measures of dispersion (standard deviation and range). 
 Results 
 Literature search 
 We identified a total of 304 articles within the databases consulted (52 
in PubMed-MEDLINE, 218 in EMBASE, and 34 in the Cochrane Library). 
 Finally, 13 articles passed through the selection process: six 
clinical trials, six meta-analyses and one systematic review. 
Figure  1 shows the flowchart of the selection process for the 
systematic review. 
 The main reasons for excluding studies were: the study focused 
on the use of statins for the prevention of AD (48%); the study 
design was different from that required (41%); and the study 
analysed different variables from those considered (8%). 
 Study characteristics 
 Table  1 shows the quality score of each study, according to the 
CASPe scale and the AMSTAR tool. Generally, all the studies 
included were of high quality, with the exception of those 
conducted by Sjogren  et al 19 and Serrano-Pozo  et al 21 because of 
their non-randomised open-label design. All the meta-analyses 
were of high scientific quality and three of them obtained the 
maximum score on the AMSTAR scale. 24,25,28 
Tables  2 and  3 show the characteristics and the efficacy 
outcomes of the clinical trials and meta-analyses selected, 
respectively. In general, the study populations comprised older 
patients diagnosed with mild–moderate AD and MMSE scores 
between 12 and 26, in most cases. 
 The systematic review performed by Xiong  et al included a total 
of nine randomised, crossover and placebo-controlled clinical trials 
that studied the cognitive effects of statins. 29 
 Clinical outcomes 
 Simons  et al did not find any significant differences in ADAS-Cog 
score between patients treated with simvastatin and those treated 
with placebo. 18 However, they found significant differences between 
both groups in terms of the MMSE score. Differences in the variation 
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 According to the open-label clinical trials performed by Sjogren 
 et al 19 and by Serrano-Pozo  et al , 21 there were no changes in 
AD markers in plasma or CSF after 12 weeks of simvastatin 
treatment (Aβ40-plasma, Aβ40-CSF, Aβ42-CSF, total tau-CSF, and 
phosphorylated tau-CSF). ADAs-Cog score and soluble amyloid 
precursor protein levels were significantly lower at the end of 
Sjogren  et al study. 19 
 In the latest clinical trials conducted by Sano  et al 7 and by 
Feldman  et al, 22 ADAS-Cog, MMSE, CGIC and NPI results were 
similar in statins (simvastatin and atorvastatin, respectively) and 
placebo patients. 
 Based on the outcomes of the meta-analyses included in this 
review, there were no differences in ADAS-Cog, MMSE, CGIC or NPI 
scores between placebo and treatment groups. 23–25 , 27,28 Gizachew 
 et al analysed four clinical trials and did not detect any variation 
in ADAS-Cog; 24 they also included nine observational studies, one 
of which analysed the effect of the use of statins in MMSE without 
detecting any differences between treatments. 
 Xiong  et al in their systematic review concluded that, although 
one study showed a slight improvement in patients treated with 
lovastatin versus placebo patients, the remaining trials did not 
show any significant differences in cognitive tests. 29 
 Discussion 
 Here, we present an updated systematic review of available 
high-quality evidence on the efficacy of statins in AD given that, 
over the past few years, many of the investigations published 
 Fig 1.  Flowchart of the selection 
process for the systematic review. 
Removed duplicated citaons (n=38)







Excluded by tle or abstract (n=210)
Excluded by full text arcles (n=38)
Full text not found (n=5)
 Table 1.  The quality and CASPe/AMSTAR scores of 
the studies examined 
Study CASPe 16 AMSTAR tool 17 Study quality
Sano  et al 7 6/6 High
Simons  et al 18 6/6 High
Sjogren  et al 19 3/6 Medium–low
Sparks  et al 20 6/6 High
Serrano  et al 21 3/6 Medium–low
Feldman  et al 22 6/6 High
Zhou  et al 23 9/11 High
Gizachew  et al 24 11/11 High
Sun  et al 25 11/11 High
Pandey  et al 26 9/11 High
Richardson  et al 27 9/11 High
McGuiness  et al 28 11/11 High
Xiong  et al 29 7/10 a High
 aQuestion number 9 not applicable. 
of Aβ40 and 24S-hydroxycholesterol levels in favour of simvastatin 
were detected in patients with MMSE scores between 20 and 26. 
 Sparks  et al observed results that favoured atorvastatin against 
placebo, according to ADAS-Cog, MMSE and CGIC scores. 20 
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 Table 3.  Characteristics and efficacy results of meta-analyses included 
Study Studies included Number of 
patients
Selection criteria  Efficacy results; n (95% CI) p-value
Zhou 
 et al 23 
Two clinical trials: Simons 2002; 
Sparks 2005
107 Patients with dementia or AD; 
randomised controlled trials
ADAS-Cog: 1.84 (–1.58, 5.27) 0.055
Gizachew 
 et al 24 
 Four clinical trials 1,153 Clinical trials and subjects with 
a history or risk of AD
ADAS-Cog: –0.57 (–1.39, 
0.25)
0.17
MMSE: 0.57 (–0.36, 1.50) 0.23
NPI: –0.77 (–1.59, 0.06) 0.07
Six observational studies 21,819 Patients diagnosed with AD or 
at risk for the disease
HR: 0.69 (0.542, 0.882)
OR: 0.447 (0.229, 0.668)
0.003
<0.001
Sun  et al 25 Two clinical trials: Sparks 2005; 
Feldman 2010
710 Patients with probable AD; 
randomised placebo-controlled 
clinical trials. Sparks 2005: 
single-centre study; Feldman 
2010: multi-centre study
ADAS-Cog: 1.05 (–3.06, 6.05)
MMSE: 0.77 (–0.57, 2.10)
CGIC: 0.13 (–0.15, 0.40)






 et al 26 
Five clinical trials: PROSPER 
2002; Simons 2002; Sparks 
2005; Feldman 2008; Sano 2011
6,958 Randomised clinical trials; 
subjects with a history or risk 
of AD
ADAS-Cog: –0.18 (–1.03, 
0.66)
ns
MMSE: –0.921 (–1.84, 
0.0055)
<0.05
CGIC: –0.26 (–3.11, 2.58) ns
Richardson 
 et al 27 
14 AD studies Patients; randomised controlled 
trials
10 cohort studies 759,553 Cohort study RR: 0.79 (0.63, 0.99)
Three case-control studies 5,758 Case-control study OR: 0.56 (0.41, 0.78)
One cross-sectional study 57,104 Cross-sectional study OR: 0.45 (0.35, 0.58)
McGuiness 
 et al 28 
Four clinical trials: Sparks 2005; 
Feldman 2010; Simons 2002; 
Sano 2011
1154 Patients with probable AD; 
clinical trials placebo controlled, 
randomised, double blind
ADAS Cog: –0.26 (–1.05, 
0.52)
MMSE: –0.32 (–0.71, 0.06)
0.51
0.099
CGIC: –0.02 (–0.14, 0.10) 0.74
NPI: –0.84 (–1.64, –0.05) 0.034
 AD = Alzheimer’s disease; ADAS-Cog = Alzheimer’s disease assessment scale-cognitive; CGIC = Clinical Global Impressions of Change; CI = confidence interval; HR = 
hazard ratio; MMSE = mini-mental state examination; NPI = neuropsychiatric inventory; ns = non-significant; OR = odds ratio; RR = relative risk 
and some clinical guidelines have included these drugs as a 
possible treatment option for AD. The studies included in this 
work highlight the limited efficacy of the use of statins in AD 
when compared with placebo. In 2001, Friedhoff  et al detected 
a decrease in serum Aβ levels after treatment with various doses 
of lovastatin in patients with elevated LDL cholesterol levels but 
not diagnosed with AD. 30 This finding opened the way to expand 
research on the use of statins in AD because, by reducing the 
formation of atheromatous plaque, the said treatment could 
prevent cognitive impairment. 
 In 2002, Simons  et al detected a small decrease in Aβ40 and 
Aβ42 levels in patients with mild–moderate AD treated with 
simvastatin. 18 However, such results were only significant in patients 
with milder AD. In addition, an improvement in MMSE scores was 
observed. For their part, Sjogren  et al performed a clinical trial with 
one active arm treated with simvastatin, and reported a reduction 
in CSF levels of α-SAPP and β-SAPP, in patients diagnosed with 
AD. 19 These results implied lower β-amyloid levels and, therefore, a 
decrease in the formation of atheromatous plaque, demonstrating 
that statins could interfere directly in the metabolism of secretases 
and in the accumulation of Aβ. 
 Likewise, in 2005, Sparks  et al conducted a trial to study the 
efficacy of a new statin (atorvastatin calcium) versus placebo 
in patients with mild–moderate AD. 20 This study measured 
ADAS-Cog, MMSE, CGIC and NPI scores, detecting differences 
between both treatment arms in the first three efficacy variables. 
Subsequently, the authors performed a post hoc analysis that 
showed that the efficacy of atorvastatin calcium was closely 
related to baseline cholesterol levels and to the apoE genotype. 31 
Hence, patients with high cholesterol levels and those who are 
carriers of the apoE ε4 allele would be more likely to benefit 
from the use of statins early in their treatment. However, the 
limitations of this type of post hoc study make it difficult to 
generalise these findings. 14 
 In 2010 and 2011, two clinical trials with larger sample sizes were 
carried out. Feldman  et al studied the efficacy of atorvastatin in 
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patients with medium–moderate AD, detecting no significant 
differences between treatment and placebo groups in ADAS-Cog, 
MMSE and CGIC scores. 22 Later, Sano  et al did not observe any 
cognitive improvement in ADAS-Cog and MMSE scores in patients 
with mild–moderate AD after treatment with simvastatin. 7 Although 
they identified a reduction in cholesterol levels in the statin treatment 
arm, their findings did not support the use of these drugs in AD. 
 After analysing the articles selected, we suggest that statins 
have not been proven to be of clear benefit for the treatment of 
AD. This claim relies on the fact that the main variables of the 
disease measured have not shown a significant improvement 
in patients treated with statins, compared with those who were 
administered a placebo. 
 Our review reinforces the findings of previous studies and 
meta-analyses carried out by Zhou  et al , 23 Gizachew  et al 24 and 
Richardson  et al , 27 in which the main variables indicating cognitive 
impairment indicated negative results on the use of statins for 
the treatment of AD. The results of our review are supported by 
our inclusion of more, high-quality, articles compared with these 
previous reports. 
 Also, Miller  et al performed a narrative review in which they 
included clinical trials investigating the use of statins and AD. 32 
According to their study, evidence suggested that these drugs 
could offer a protective effect against the development of AD 
and had been proven to be useful as long-term therapy for 
hyperlipidaemia. However, the authors concluded that available 
studies assessing the use of statins had numerous confusing 
variables possibly skewing results and, therefore, they might not 
provide suitable clinical evidence as to whether these agents have 
an effect on the progression of AD. Hence, the authors did not 
recommend the use of statins as prophylaxis in patients with AD 
without hyperlipidaemia. 
 Additionally, patients diagnosed with AD are usually older and 
most have multimorbidities, frequently treated with polypharmacy. 33 
It is essential to apply measures to reduce the number of drugs in 
these patients, with the purpose of preventing adverse reactions, 
improving adherence and reducing costs. Indeed, it is necessary to 
deprescribe drugs whose risk–benefit balance is controversial. 34 Given 
the efficacy demonstrated by statins for the treatment of AD, these 
drugs can be considered as susceptible to this process. 
 Among the limitations of our review is the delay between the 
date when the article search was finished (April 2016) and the 
date of its publication, which resulted from the high number of 
studies that were reviewed. Also, we have only considered studies 
that analyse the use of statins as treatment for AD and did not 
include those that analysed these drugs as prophylaxis against the 
disease. However, other systematic reviews on this topic have been 
recently published and, therefore, in this case, it would be difficult 
to provide relevant evidence in this regard. 
 Nevertheless, the present study includes updated information 
with a high level of evidence on the poor efficacy of the use of 
statins for the treatment of AD. 
 Conclusions 
 Although some previous studies suggest that the use of statins could 
offer a protective effect against AD, according to available evidence, 
the studies examined here do not provide enough evidence and do 
not show conclusive results that support the efficacy of statins for 
the treatment of AD. Therefore, the use of statins as treatment for 
this disease should not be recommended. ■
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